罕见病知识库 RareSeen

骨巨细胞瘤

Giant cell tumor of bone

ORPHA:363976疾病中国目录 第2批 · 36

定义

本病是一种罕见的骨肉瘤,其特征是通常为良性的占位性病变,但仍具有局部侵袭性,并会严重破坏周围的骨组织。该肿瘤由分泌髓样前体和破骨前因子的巨多核细胞(破骨细胞样细胞),单核巨噬细胞和单核基质细胞组成。转移和恶性转化很少见,但复发率很高。

别名

骨巨细胞瘤

基本事实

遗传方式
不适用
发病年龄
成年期
患病率
1-9 / 1 000 000

近两年的全球研究 479L2

2024/10 起在 Europe PMC 检索所得,按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务,尚未引入。

  • 2026-09综述开放获取
    Virotherapy for Spinal and Spinal Cord Tumors: Current Evidence and Future Perspectives
    Microorganisms · DOI · Europe PMC
  • 2026-09综述开放获取
    Decoding Skeletal Biology Through Transcriptomics: Insights from Bulk, Single-Cell, Spatial, and Multi-Omics Approaches
    International journal of molecular sciences · DOI · Europe PMC
  • 2026-09综述开放获取
    Infiltrative and inflammatory systemic disorders involving the pituitary gland
    Pituitary · DOI · Europe PMC
  • 2026-09
    Successful Denosumab Treatment of a Pediatric Spinal Aneurysmal Bone Cyst With COL1A1-USP6 Rearrangement Histologically Mimicking Giant Cell Tumor of Bone
    Pediatric blood & cancer · DOI · Europe PMC
  • 2026-09
    Clinicopathological characteristics of giant cell tumor of bone and identification of a novel H3F3A p.V36_K37insL mutation
    Pathology, research and practice · DOI · Europe PMC
  • 2026-09病例报告
    Total en bloc resection of a giant cell tumour of the cervical spine involving the vertebral artery
    BMJ case reports · DOI · Europe PMC
  • 2026-09
    The clinical, functional and oncological outcomes of patients with giant cell tumour of bone. A long-term review
    Journal of orthopaedic surgery (Hong Kong) · DOI · Europe PMC
  • 2026-09
    Nano-RAPID: Integrated Diagnosis for Sarcoma Using a Nanopore Sequencer
    Genes, chromosomes & cancer · DOI · Europe PMC
  • 2026-09病例报告开放获取
    Proximal Tibial Giant Cell Tumor in a Skeletally Immature Child: A Diagnostic Dilemma and Review of the Literature
    Journal of orthopaedic case reports · DOI · Europe PMC
  • 2026-09病例报告开放获取
    Acetabular Giant Cell Tumor Presenting with Protrusio Acetabuli: A Rare Case Report
    Journal of orthopaedic case reports · DOI · Europe PMC
  • 2026-09病例报告
    Spinopelvic Reconstruction for a Giant Cell Tumor Involving the Sacroiliac Joint: A Case Report
    Anticancer research · DOI · Europe PMC
  • 2026-09开放获取
    Immunoexpression of CXCL12 and CXCR4 in giant cell granulomas of the jaws and giant cell tumor of bone
    Medicina oral, patologia oral y cirugia bucal · DOI · Europe PMC
  • 2026-08病例报告开放获取
    Giant Cell Tumor of the Distal Ulna in an Elderly Patient on Hemodialysis: Diagnostic Challenge and Surgical Management
    Cureus · DOI · Europe PMC
  • 2026-08
    De novo osteosarcoma following prolonged denosumab treatment for giant cell tumor of bone at an anatomically distant site: a case report
    Skeletal radiology · DOI · Europe PMC
  • 2026-08综述
    Histone tail mutants: versatile tools for decoding chromatin, development, and disease
    Trends in genetics : TIG · DOI · Europe PMC
  • 2026-08开放获取
    10th International Conference on Osteoimmunology: Interactions of the Immune and Skeletal Systems
    JBMR plus
  • 2026-08
    Temporal changes in Denosumab use among patients with giant cell tumour of bone at a specialist oncology centre: a retrospective cohort study
    Cancer treatment and research communications · DOI · Europe PMC
  • 2026-08病例报告开放获取
    Multicentric metachronous giant cell tumor of the femur: a rare case report and review of the literature
    International journal of surgery case reports · DOI · Europe PMC
  • 2026-08开放获取
    Long-Term Outcomes and Risk Factors for Implant Failure After Distal Femoral Megaprosthesis in Orthopaedic Oncology: A Single-Center Retrospective Study
    Arthroplasty today · DOI · Europe PMC
  • 2026-08
    Efficacy of Neoadjuvant Denosumab on Tumor Recurrence, Ossification, and Surgical Outcomes in Patients With Grade III Giant Cell Tumor of Bone: A Prospective, Non-Randomized Comparative Interventional Study
    Asia-Pacific journal of clinical oncology · DOI · Europe PMC

国家医保药品目录中点名本病的药品 1L2

出自《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》(医保发〔2025〕33号,2026-01-01 起执行)。下列药品在药品名称或限定支付范围里出现了本病的名称。

匹配不到 ≠ 不能报销。目录里只有约一成药品设了限定支付范围,其余按适应症正常使用同样可报销;本区块只能回答「目录有没有点名这个病」,不能回答「这个病有没有药能报销」。各省执行细则、双通道与单独支付范围另有规定,请以当地医保部门口径为准。

  • 纳鲁索拜单抗注射液乙类谈判药品
    限不可手术切除或手术切除可能导致严重功能障碍的骨巨细胞瘤成人患者。

境外已获批用于本病的药物 2L2

欧盟 1 项、美国 1 项。同一药物在两地各批一次的,会分别列出。

「境外已获批」不等于「在中国能用」。中间隔着进口注册、临床急需境外新药通道、海南博鳌乐城国际医疗旅游先行区等几条路径,各有各的条件与费用。这一节能确定地告诉你的只有一件事:这个病在世界范围内已经有获得批准的药物,它叫什么名字。拿这个名字去问主治医生,是下一步最省力的做法。

药名一律保留英文原文,不作翻译——中国的药品通用名与英文名的音译经常不一致,译错会让人去找一个不存在的药。

数据来自欧洲药品管理局(EMA)的药品与罕见病用药资格公开导出表,以及美国 FDA 的罕见病用药资格数据库(Orphan Drug Product Designation Database)。两边口径不同:欧盟一侧取的是当前状态仍为「已授权」的药品;美国一侧记录的是「曾获批准」这一事实,FDA 的公开表不追踪药物此后是否退市(例如 Relyvrio 于 2024 年撤市,表中仍记为已获批)。请以官方记录页为准。

在中国开展的临床试验 11L2

按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实,并与主治医生商量。

登记为可入组 5

  • 招募中NCT05595603
    Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage
    II 期 · 干预性 · 2023/03Second Affiliated Hospital, Zhejiang University, School of Medicine
    中国研究中心 1 个:Hangzhou
  • 尚未开始招募NCT05813665
    A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone
    III 期 · 干预性 · 2023/04Shanghai JMT-Bio Inc.
    中国研究中心 1 个:Beijing
  • 招募中NCT06302465
    Narlumosbartmab Combined With Neoadjuvant Chemotherapy in Bone-derived Malignancies With Osteolytic Lesions and Multinucleated Giant Cells
    不适用 · 干预性 · 2024/05/01Peking University People's Hospital
    中国研究中心 1 个:Beijing
  • 招募中NCT06647901
    Efficacy of ICG-based NIR Imaging in Intralesional Curettage of Giant Cell Tumors of Bone in Limbs: a Prospective, Single-center, Single-arm, Open Study
    I 期、II 期 · 干预性 · 2024/08/23Tang Xiaodong
    中国研究中心 1 个:Beijing
  • 招募中NCT07315828
    Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Giant Cell Tumor of Bone Surgery
    IV 期 · 干预性 · 2026/01/02Shanghai Jiao Tong University Affiliated Sixth People's Hospital
    中国研究中心 1 个:Shanghai
其他状态的试验(6 项)
  • 已完成NCT06331104
    Network Pharmacology Prediction: Mechanism Study of Puerarin in the Treatment of Giant Cell Tumors of Bone
    观察性 · 2012/06/14Changye Zou
    中国研究中心 1 个:Guangzhou
  • 状态未知NCT03259152
    Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone
    III 期 · 干预性 · 2016/05/01Hebei Medical University Third Hospital
    中国研究中心 1 个:Shijiazhuang
  • 状态未知NCT04255576
    Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone
    I 期、II 期 · 干预性 · 2019/10/10Shanghai JMT-Bio Inc.
    中国研究中心 1 个:Beijing
  • 已完成NCT04952818
    The Value of Preoperative Diagnosis and Prognostic Prediction Based on Radiomics of Giant Cell Tumor of Spine
    观察性 · 2020/01/01Peking University Third Hospital
    中国研究中心 1 个:Beijing
  • 已完成NCT05402865
    A Real-world Study on Patients of Unresectable Giant Cell Tumor of Bone
    观察性 · 2021/11/10Shanghai JMT-Bio Inc.
    中国研究中心 3 个:Beijing
  • 进行中·不再招募NCT04586660
    Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone
    IV 期 · 干预性 · 2023/08/17Amgen
    中国研究中心 8 个:Beijing、Fuzhou、Guangzhou、Hangzhou、Harbin、Xi'an

中国境外的在招试验 10L2

这些试验在中国没有研究中心,通常无法直接报名——入组一般要求在当地居住并接受随访。列在这里是因为它另有用处:看清楚全世界正在试哪些药、做到了哪一期、由谁在做。把药名和 NCT 编号记下来去问主治医生,或据此进一步查该药是否已在境外获批、是否有拓展性用药(expanded access)通道。

美国4加拿大2捷克1印度1

CT.gov 报告命中 10 项,此处取回并展示最近的 5 项。

  • 招募中NCT07609277
    TRACP-5b for Diagnosis and Follow-up of Giant Cell Tumor of Bone
    观察性 · 2026/01/01St. Anne's University Hospital Brno, Czech Republic
    捷克
  • 招募中NCT07227961
    PROMIS and Mobility Evaluation in Sarcoma Patients
    观察性 · 2025/07/01University of Calgary
    加拿大、美国
  • 招募中NCT06239272
    NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
    I 期、II 期 · 干预性 · 2024/03/27St. Jude Children's Research Hospital
    美国
  • 招募中NCT05463796
    InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
    观察性 · 2023/04/25Dana-Farber Cancer Institute
    美国
  • 招募中NCT03295981
    Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
    III 期 · 干预性 · 2018/05/03St. Louis University
    加拿大、印度、美国

外部标识与链接

OrphanetMONDO:0005674GARD:13046ICD-10 D48.0ICD-11 2F7B、2F9B、XH0492、XH4TC2ClinicalTrials.gov 检索

发现这一页有错误?告诉我 · 邮件主题会自动带上本页的 ORPHA 编号

本页数据来源

  • 疾病定义、同义词、基因、表型、流行病学:Orphanet(CC BY 4.0)
  • 中文病名:Orphanet 中文包,冻结于 2020-06-01
  • 表型中文标签:HPO 简体中文翻译(CHPO 上游成果)